医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Promethera Biosciences: Announcement Regarding Business Activities in Japan

2019年10月31日 PM06:30
このエントリーをはてなブックマークに追加


 

MONT-SAINT-GUIBERT, Belgium & TOKYO

Promethera Biosciences SA (Group), a global innovator in cell-based medicines and liver diseases, announced the foundation of a new branch office in Tokyo, Promethera Biosciences Japan Branch Ltd on May, 2018. Establishing a branch office in Japan marks the starting point for building a strong presence of Promethera in Japan first, initially focusing on increased Business Development, Investor Relations activities and expansion of its business and products pipeline in Japan. This presence will also address the Asian markets as a second step.

As we develop such business activities, we are considering various options for further strengthening our presence in Japan. These options include future listing on the Tokyo Stock Exchange Market (whether or not using a Japanese Depositary Receipt (JDR scheme*) or another Asian stock exchange, and/or partnering with pharmaceuticals.

*for more information of the JDR scheme, please see
https://www.jpx.co.jp/english/equities/listing-on-tse/new/basic/05.html

About Promethera Biosciences:

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline, we develop antibody technologies such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert (Belgium), Durham (NC, USA), Tokyo (Japan) and Basel (Switzerland).

Promethera®, HepaStem®, H2stem®, are all registered trademarks of the PROMETHERA group.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191031005412/en/

CONTACT

Promethera Biosciences Japan Branch

Mutsuki Takano, Group CFO / Masumi Akahori, Senior IR Manager

info.japan@promethera.com

Tel: +81 (0)3-5843-6077

Web: www.promethera.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作